Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice. - Wikidata - wikimedia - TriplyDB

Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.

Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.

http://www.wikidata.org/entity/Q37991783

about

Current and emerging treatment options for patients with relapsed myeloma Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma.Choosing treatment options for patients with relapsed/refractory multiple myeloma.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression

P2860

Q26830878-B9C6697C-95A6-4574-9F4E-E8E6717E264C Q38103585-4CC4E3B6-9114-41B0-A711-35C4EB283EB0 Q38130301-B72FEC08-B37B-434C-8539-DE17CCD264CA Q38170453-4C9BA25B-7641-4DD6-A07F-92F1D077335E Q39136762-77FC2962-D9DF-4E63-AE08-8DE392939C3E

P2860

Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.

http://www.wikidata.org/entity/Q37991783

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Immunomodulatory drugs in mult ...... f action to clinical practice.

@en

Immunomodulatory drugs in mult ...... f action to clinical practice.

@nl

type

label

Immunomodulatory drugs in mult ...... f action to clinical practice.

@en

Immunomodulatory drugs in mult ...... f action to clinical practice.

@nl

prefLabel

Immunomodulatory drugs in mult ...... f action to clinical practice.

@en

Immunomodulatory drugs in mult ...... f action to clinical practice.

@nl

P1433

Q37991783-82CB41A5-C4B9-4888-9A8D-E2F8E3D44DC3

P1476

Q37991783-D16E9F1A-048A-41BB-92DF-D61CA8D5B900

P2093

Q37991783-11AE2130-EF5F-4684-8817-A72FEEA5B9F0

Q37991783-32D27442-3014-415E-AA62-262E7739FF7F

Q37991783-5203CD48-68E0-485B-88B3-AED2B4FF2187

Q37991783-53F7DCA3-EBD6-4822-8548-F78526AACE6F

Q37991783-941F191B-87CF-4737-90D3-C4954E746046

P2860

Q37991783-08CB0914-0DD7-4DE0-9043-C2AD6D6F3D16

Q37991783-0A08BD07-1A7E-497E-A474-B07B02321CF8

Q37991783-0BA26A26-D7EA-45F8-A8AC-E1104AF5571C

Q37991783-0D5718DA-E5D4-47BE-8094-D11EF70119D5

Q37991783-1030B905-513F-4C05-A2BC-964A4042C5A3

Q37991783-15005CB1-29FB-4DAA-A8AB-FEB4A7237C39

Q37991783-1962F52D-8BD3-4D59-8E7B-75E25B793E9A

Q37991783-1E2BEE88-0018-4F51-8F39-F814D15F6875

Q37991783-2714615E-08A6-4C3A-98BA-03E22005F862

Q37991783-2A81CDFA-0A8C-408E-A677-4D52B1DDBC67

P304

Q37991783-AF78DF2E-A979-4FED-9265-045F70678297

P31

Q37991783-BA6DFC2B-15E8-4438-9555-923B4D898C85

P356

Q37991783-9D61E8DB-E581-4A54-95A7-4958E359B051

P433

Q37991783-DF5D2647-94B9-42F4-9193-D5C3B4EFC1AC

P478

Q37991783-112F1631-95C3-4C9F-8E6B-82719168165C

P577

Q37991783-67FD7894-0CC4-4D3C-BDCD-8D061750AB21

P5875

Q37991783-A12A2103-CEAD-4F69-8A5C-8D8827B6CD6E

P698

Q37991783-8F275F2C-A830-45A9-959F-8A74F9B7234A

P356

08923973.2012.658921

P1433

Immunopharmacology and Immunotoxicology

P1476

Immunomodulatory drugs in mult ...... f action to clinical practice.

@en

P2093

Agostino Cortelezzi

http://www.w3.org/2001/XMLSchema#string

Antonino Cannavò

http://www.w3.org/2001/XMLSchema#string

Fabio Conforti

http://www.w3.org/2001/XMLSchema#string

Giovanni Grava

http://www.w3.org/2001/XMLSchema#string

Roberto Castelli

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

P304

740-753

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/08923973.2012.658921

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221891075

http://www.w3.org/2001/XMLSchema#string

P698

22401643

http://www.w3.org/2001/XMLSchema#string